Strategic decisions made early in clinical development often have an impact on the downstream commercial potential of an asset. This is true for both large pharma and emerging biotech companies. What choices must be made during early clinical development? What are the trade-offs to consider? How do these key decisions affect the commercial potential, partnering opportunities, and ability to invest in other assets in a therapeutic franchise or overall pipeline?